• Bean Gray posted an update 6 months, 1 week ago

    AT2 can promote the growth and proliferation and suppress the apoptosis of CRC cells. The changes in lncRNA CCAT2 expression are associated with poor prognosis.

    Laparoscopic complete mesorectal excision (CME) can be used for the treatment of colon cancer. This study was designed to assess short-term and long-term outcomes of laparoscopic CME in elderly colon cancer patients.

    We retrospectively reviewed colon cancer patients who underwent laparoscopic CME at a single medical center between January 2014 and January 2019. Short-term surgical outcomes and long-term survival outcomes were analyzed, including overall survival (OS) and disease-free survival (DFS).

    A total of 152 patients were included in the study, of which 54 were classified as elderly group (≥70 years) and 98 were classified as younger group (<70 years). The elderly group had more Charlson comorbidity index (CCI) scores >3. The short-term results of the two groups were similar. The overall complication and major complication rates were comparable between the two groups. The 5-year OS rates of the elderly and younger groups were 67% and 71%, respectively (p=0.846). The 5-year DFS rates in the elderly and younger groups were 59% and 62%, respectively (p=0.995).

    Compared with younger patients, laparoscopic CME in elderly colon cancer patients can achieve similar short-term and long-term outcomes. For elderly colon cancer patients, age is not a contraindication to laparoscopic CME.

    Compared with younger patients, laparoscopic CME in elderly colon cancer patients can achieve similar short-term and long-term outcomes. For elderly colon cancer patients, age is not a contraindication to laparoscopic CME.

    G-protein receptors belong to a large family of receptors which includes more than 800 kinds. An interest for these receptors arose upon noticing their expression on skin, intestine and breast stem cells.

    We examined the tissues of 53 patients who had been diagnosed with adenocarcinoma of the colon. There were no exclusion criteria. We measured the expression levels of LGR5 by immunohistochemistry and we correlated those and the location of the colon primary tumor with the age, sex and the metastatic potential.

    The median values of the two groups- the orthosigmoid and the other colon location- were 1 and 3.5 respectively with no statistical significance and with p=0.132. Spearman Rho indicated no statistical significance between the expression of LGR5 and age with p=0.219. Moreover, the Mann-Whitney U test showed no statistical significance between LGR5 and sex with p=0.778. Fisher’s test, however, showed a statistically significant result between metastasis and expression of LGR5 with p=0.025.

    It becomes apparent that patients with increased expression of these two markers are characterized by a more aggressive form of the disease with an increased rate of metastasis. Also, interactions on both paths lead to a simultaneous overexpression, thus proving the diversity of carcinogenic pathways. Racial and other factors are not affected, and ultimately the need to target these indicators in treatment protocols is imperative.

    It becomes apparent that patients with increased expression of these two markers are characterized by a more aggressive form of the disease with an increased rate of metastasis. Also, interactions on both paths lead to a simultaneous overexpression, thus proving the diversity of carcinogenic pathways. Racial and other factors are not affected, and ultimately the need to target these indicators in treatment protocols is imperative.

    Breast cancer is responsible for high morbidity and mortality across the globe. Studies are focusing to develop novel systemic therapies for the treatment of this disease. The present study was designed to examine the anticancer effects of Shionone against human breast cancer cells along with the underlying mechanism of its action.

    The breast cancer SK-BR-3 and normal breast MB-157 cell lines were used in the study. CCK8 assay was used for cell viability assessment. DAPI was used for the assessment of nuclear morphology. Acridine orange (AO)/ ethidium bromide (EB) and annexin V/propidium iodide (PI) assays were used for detection of apoptosis. selleck inhibitor Cell cycle analysis was done by flow cytometry. Protein expression was examined by western blot analysis.

    The results showed that in vitro administration of Shionone led to decline of proliferation of breast cancer cells. The reduction of proliferative rates was attributed to the induction of apoptosis of breast cancer cells. Shionone caused cleavage of caspase-3 and 9. The expression of Bax was increased and that of Bcl-2 was decreased upon Shionone treatment. The transwell assays showed that Shionone suppressed the migration and invasion of breast cancer cells in a dose-dependent manner. Finally, western blot analysis showed that Shionone blocked the Ras/Raf/MEK/ERK and STAT3 signaling pathways in breast cancer cells.

    Taken all together, the study established the anticancer role of triterpenoid Shionone in restricting the growth and proliferation of human breast cancer cells.

    Taken all together, the study established the anticancer role of triterpenoid Shionone in restricting the growth and proliferation of human breast cancer cells.

    To explore the efficacy and safety of bevacizumab combined with docetaxel in the treatment of human epidermal growth factor receptor-2 (HER-2)-negative recurrent metastatic breast cancer.

    The clinical data of 128 patients with HER-2-negative recurrent metastatic breast cancer treated in our hospital from January 2015 to December 2016 were retrospectively analyzed. Sixty-four patients were treated with bevacizumab combined with docetaxel (Bevacizumab group), while the remaining 64 patients were treated with docetaxel alone (Docetaxel group). The clinical efficacy and adverse reactions were compared between the two groups, and the expressions of Ki-67, p53, matrix metalloproteinase-2 (MMP-2) and MMP-9 in breast cancer tissues were compared in both groups before and after treatment. The patient survival status and progression of disease were recorded through follow-up.

    In Bevacizumab group and Docetaxel group, the objective response rate (ORR) was 57.8% and 39.1%, and the clinical benefit rate (CBR) was 90.

All content contained on CatsWannaBeCats.Com, unless otherwise acknowledged,is the property of CatsWannaBeCats.Com and subject to copyright.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account